Add Yahoo as a preferred source to see more of our stories on Google. Chinese health experts are raising concerns about the growing interest among parents to use synthetic human growth hormones on ...

SINGAPORE, May 29, 2025 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce the Australian registration of SKYTROFA® (lonapegsomatropin) as a new ...

Children born small for gestational age (SGA) exhibited impaired glucose-insulin metabolism, similar to children with obesity, which worsened under growth hormone therapy. In contrast, children with ...

Sogroya is a long-acting form of somatropin. Somatropin is also called human growth hormone. Sogroya is made by attaching human growth hormone to a small protein that helps it stay in the body longer ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved long-acting once-weekly somatrogon for children with growth hormone deficiency. Somatrogon was ...

The FDA approved long-acting injectable somatrogon (Ngenla) for pediatric human growth hormone deficiency, developers Pfizer and OPKO Health announced this week. Somatrogon is indicated for children ...

Children with growth hormone deficiency (GHD) had reduced physical fitness and lower levels of physical activity than control individuals without the condition, but 1 year of growth hormone ...

NEW YORK (Reuters Health) - Type 2 diabetes is eight and a half times more common among children in the United States treated with growth hormone than among kids who are not on the hormone treatment, ...

SKYTROFA® (lonapegsomatropin) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of paediatric growth hormone deficiency.[1] "We are delighted to have secured TGA ...